Amgen's biosimilar candidate ABP 501 has shown comparable results in phase III, measured against AbbVie's blockbuster Humira (adalimumab), for patients with moderate-to-severe plaque psoria
Abbott's blockbuster rheumatoid arthritis drug, Humira, has been approved by the US FDA for a new use - to treat patients with moderate to severe ulcerative colitis. Abbott Laboratories Inc.'s drug, Humira, has been approved for the treatment of moderate to...
